investment image


Mirae Asset Global Investments Co. Ltd. expanded its holdings in shares of Quest Diagnostics Incorporated (NYSE: DGX– Obtain Ranking) by 19.5% during the 1st quarter, according to its latest 13F declaring with the Securities as well as Exchange Commission. The company possessed 64,245 shares of the medical research study business’s supply after acquiring an added 10,467 shares during the period. Mirae Possession Global Investments Co. Ltd. had approximately 0.05% of Quest Diagnostics worth $8,791,000 at the end of one of the most current reporting period.

A variety of various other big capitalists have likewise customized their holdings of the business.

HM Payson & Co. boosted its holdings in Quest Diagnostics by 0.7% during the fourth quarter.
HM Payson & Co. now owns 13,838 shares of the clinical research company’s stock worth $2,394,000 after buying an added 100 shares in the last quarter. Williams Jones Riches Administration LLC. expanded its holdings in shares of Quest Diagnostics by 2.0% in the fourth quarter. Williams Jones Riches Administration LLC. currently owns 5,288 shares of the clinical research company’s supply worth $915,000 after obtaining an additional 102 shares during the period. Individual CFO Solutions LLC raised its stake in Quest Diagnostics by 1.6% in the first quarter. Personal CFO Solutions LLC now has 6,382 shares of the clinical research study firm’s stock valued at $873,000 after buying an additional 103 shares in the last quarter. Freestone Funding Holdings LLC increased its holdings in Quest Diagnostics by 6.4% throughout the 4th quarter. Freestone Funding Holdings LLC currently has 2,025 shares of the medical study business’s stock worth $350,000 after purchasing an added 121 shares throughout the last quarter. Lastly, Financial Benefit Inc. boosted its setting in Quest Diagnostics by 0.6% throughout the very first quarter. Financial Benefit Inc. now has 21,679 shares of the medical research study firm’s stock worth $2,966,000 after buying an added 121 shares in the last quarter. 89.89% of the stock is had by hedge funds as well as various other institutional financiers.

Wall Street Analyst Weigh In.

Numerous research experts have actually lately issued records on DGX shares. StockNews.com raised Quest Diagnostics from a “hold” ranking to a “get” rating in a research note on Thursday, July 7th. Wells Fargo & Company raised their target cost on shares of Quest Diagnostics from $145.00 to $150.00 and also offered the stock an “equivalent weight” rating in a research report on Monday, April 25th. Finally, UBS Group boosted their rate target on shares of Quest Diagnostics from $139.00 to $150.00 in a research report on Sunday, April 24th. Six equities study experts have actually ranked the stock with a hold rating as well as 3 have provided a buy rating to the firm. According to MarketBeat.com, the company currently has an agreement score of “Hold” as well as an ordinary cost target of $148.80.

Quest Diagnostics Stock Performance.

Shares of DGX opened up at $135.48 on Friday. Quest Diagnostics Incorporated has a 1 year low of $125.33 and also a 1 year high of $174.16. The business’s 50 day straightforward relocating average is $135.42 and also its 200 day simple moving average is $136.37. The company has a market capitalization of $15.80 billion, a price-to-earnings ratio of 11.27 and a beta of 1.00. The business has a debt-to-equity proportion of 0.62, a fast ratio of 1.42 and also a present ratio of 1.54.
Quest Diagnostics (NYSE: DGX– Get Score) last released its quarterly revenues outcomes on Thursday, July 21st. The medical research study business reported $2.36 profits per share for the quarter, defeating the agreement estimate of $2.26 by $0.10. Quest Diagnostics had a return on equity of 24.62% and a net margin of 14.02%. The company had profits of $2.45 billion throughout the quarter, compared to the agreement quote of $2.34 billion. During the exact same duration in the previous year, the company uploaded $3.18 EPS. Quest Diagnostics’s income was down 3.8% on a year-over-year basis. On average, sell-side analysts anticipate that Quest Diagnostics Incorporated will certainly upload 9.69 EPS for the present year.

Quest Diagnostics Announces Returns.

The firm also recently proclaimed a quarterly dividend, which will certainly be paid on Wednesday, October 19th. Shareholders of record on Tuesday, October fourth will be paid a $0.66 returns. This represents a $2.64 dividend on an annualized basis and also a return of 1.95%. The ex-dividend date of this reward is Monday, October 3rd. Quest Diagnostics’s payout proportion is 21.96%.

Insider Trading at Quest Diagnostics.

In various other information, Director Timothy M. Ring marketed 2,000 shares of the stock in a transaction dated Friday, July 1st. The shares were sold at an ordinary rate of $133.47, for an overall deal of $266,940.00. Complying with the transaction, the supervisor currently directly owns 23,933 shares in the company, valued at about $3,194,337.51. The sale was divulged in a legal declaring with the SEC, which is readily available at this link. In relevant news, Director Timothy M. Ring offered 2,000 shares of the company’s supply in a deal that happened on Friday, July 1st. The shares were cost an ordinary cost of $133.47, for a total deal of $266,940.00. Adhering to the conclusion of the transaction, the director now has 23,933 shares of the company’s stock, valued at $3,194,337.51. The sale was disclosed in a document submitted with the Stocks & Exchange Payment, which is accessible through the SEC website. Also, Chief Executive Officer Stephen H. Rusckowski marketed 282,408 shares of the supply in a transaction that happened on Tuesday, May 24th. The supply was sold at an average price of $140.12, for a complete deal of $39,571,008.96. Following the purchase, the chief executive officer now straight has 334,833 shares in the company, valued at around $46,916,799.96. The disclosure for this sale can be located right here. Experts marketed 286,408 shares of company supply worth $40,110,029 in the last 90 days. 1.70% of the stock is had by firm insiders.

The Quest Diagnostics Firm Profile.

Quest Diagnostics Incorporated offers diagnostic testing, details, as well as services in the United States and also globally. The business establishes and also supplies analysis info services, such as routine screening, non-routine as well as sophisticated clinical testing, structural pathology testing, and also other diagnostic info services.

Leave a Reply

Your email address will not be published.